SCHEMBL4889569

SCHEMBL4889569

CCCCc1ccc2c(c1)Cc1cc(CCCC)ccc1-2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SKP2 Q13309 1/20 0.47
HTR2A P28223 2/20 0.47
DRD2 P14416 1/20 0.47
SLC6A2 P23975 1/20 0.47
HTR2C P28335 1/20 0.47
SLC6A4 P31645 1/20 0.47
GPR3 P46089 1/20 0.42
NPSR1 Q6W5P4 2/20 0.42
HPGD P15428 2/20 0.42
NPC1 O15118 2/20 0.42
MAPK1 P28482 2/20 0.42
RAB9A P51151 2/20 0.42
HTT P42858 1/20 0.42
ALDH1A1 P00352 2/20 0.41
TSHR P16473 1/20 0.41
ATM Q13315 1/20 0.41
MLNR O43193 1/20 0.41
S1PR1 P21453 1/20 0.41
CA2 P00918 2/20 0.41
CA1 P00915 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2930325 0.94 HTR2A (0.52) HTR2ADRD2SLC6A2HTR2CSLC6A4
SCHEMBL31228811 0.94 HTR2A (0.52) HTR2ADRD2SLC6A2HTR2CSLC6A4
SCHEMBL4887234 0.92 HTR2A (0.55) HTR2ADRD2SLC6A2HTR2CSLC6A4
SCHEMBL4895814 0.92 HTR2A (0.55) HTR2ADRD2SLC6A2HTR2CSLC6A4
SCHEMBL4898274 0.92 HTR2A (0.55) HTR2ADRD2SLC6A2HTR2CSLC6A4
SCHEMBL4900272 0.92 HTR2A (0.55) HTR2ADRD2SLC6A2HTR2CSLC6A4
SCHEMBL30369240 0.92 HTR2A (0.55) HTR2ADRD2SLC6A2HTR2CSLC6A4
SCHEMBL11843513 0.91 TSHR (0.54) SKP2HTR2ADRD2SLC6A2HTR2C
SCHEMBL29566807 0.91 TSHR (0.54) SKP2HTR2ADRD2SLC6A2HTR2C
SCHEMBL28895060 0.90 NPC1 (0.49) SKP2HTR2ADRD2SLC6A2HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101107260-B Transition metal complex, method for producing the same, substituted fluorene compound, method for producing the substituted fluorene compound, catalyst component for olefin polymerization, catalyst for olefin polymerization, and method for producing olefin polymer SUMITOMO CHEMICAL CO.,LTD. (JP) 2012-02-08 CN disclosed
US-8084559-B2 Ethylene-vinylcyclohexane copolymers SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-12-27 US disclosed
US-20080161514-A1 Transition Metal Complex, Process For Producing Said Transition Metal Complex, Substituent-Carrying Fluorene Compound, Process For Producing Said Fluorene Compound, Catalyst Component For Olefin Polymerization, Catalyst For Olefin Polymerization, and Process For Producing Olefin Polymer SUMITOMO CHEMICAL COMPANY, LIMTIED (JP) 2008-07-03 US disclosed
CN-101107260-A Transition metal complex, method for producing the same, substituted fluorene compound, method for producing the substituted fluorene compound, catalyst component for olefin polymerization, catalyst for olefin polymerization, and method for producing olefin polymer SUMITOMO CHEMICAL CO (JP) 2008-01-16 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161514-A1 Transition Metal Complex, Process For Producing Said Transition Metal Complex, Substituent-Carrying Fluorene Compound, Process For Producing Said Fluorene Compound, Catalyst Component For Olefin Polymerization, Catalyst For Olefin Polymerization, and Process For Producing Olefin Polymer AOC2, ACSL1, ACSL3 SKP2 197/4885HTR2A 4366/4885DRD2 2423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.